HEALTHSTAT NEWS
STAT+: The end for GSK’s chronic cough treatment
The article discusses the end of GSK’s chronic cough treatment and highlights a gene therapy approach generating both excitement and skepticism. It also mentions Jennifer Doudna’s work on AI-designed gene editors and Kalshi’s expansion into biotech.
Mentioned
Related Signal
Adjacent reporting
- STAT+: Pharmalittle: We’re reading about rising drug shortages, GSK coughing up a trial loss, and more
- Opinion: $2 million gene therapy cures require a financing model
- STAT+: A turning point for pancreatic cancer patients
- STAT+: Roche drug sets new standard for KRAS-driven lung cancer
- STAT+: Roche ends Huntington’s gene-silencing programs
- STAT+: Pharmalittle: We’re reading about a Lilly gene therapy for cholesterol, three new Lilly deals, and more